MA37799B2 - Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci - Google Patents

Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci

Info

Publication number
MA37799B2
MA37799B2 MA37799A MA37799A MA37799B2 MA 37799 B2 MA37799 B2 MA 37799B2 MA 37799 A MA37799 A MA 37799A MA 37799 A MA37799 A MA 37799A MA 37799 B2 MA37799 B2 MA 37799B2
Authority
MA
Morocco
Prior art keywords
dyspareunia
symptoms
sexual
orgasm
dha
Prior art date
Application number
MA37799A
Other languages
English (en)
Other versions
MA37799A1 (fr
Inventor
Fernand Labrie
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49996456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37799(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of MA37799A1 publication Critical patent/MA37799A1/fr
Publication of MA37799B2 publication Critical patent/MA37799B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une dha intra vaginale utilisée pour le traitement d'au moins un état choisi dans le groupe constitué par un trouble hypoactif du désir sexuel féminin, un trouble de l'excitation sexuelle féminine, un trouble de l'orgasme féminin et un trouble de stimulation de l'intérêt sexuel féminin chez une femme qui (1) ne souffre pas de symptômes d'atrophie vulvo-vaginale et/ou (2) ne souffre pas de dyspareunie de modérée à aiguë.
MA37799A 2012-07-25 2013-07-18 Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci MA37799B2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675717P 2012-07-25 2012-07-25
US13/942,977 US20140045806A1 (en) 2012-07-25 2013-07-16 Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
PCT/CA2013/000654 WO2014015416A1 (fr) 2012-07-25 2013-07-19 Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci

Publications (2)

Publication Number Publication Date
MA37799A1 MA37799A1 (fr) 2016-08-31
MA37799B2 true MA37799B2 (fr) 2021-02-26

Family

ID=49996456

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37799A MA37799B2 (fr) 2012-07-25 2013-07-18 Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci

Country Status (25)

Country Link
US (1) US20140045806A1 (fr)
EP (1) EP2877183B1 (fr)
JP (3) JP2015522625A (fr)
KR (4) KR102258122B1 (fr)
CN (2) CN111529536A (fr)
AR (1) AR091907A1 (fr)
BR (1) BR112015001479A2 (fr)
CA (2) CA2972491C (fr)
CL (1) CL2015000169A1 (fr)
DK (1) DK2877183T3 (fr)
EA (1) EA028263B1 (fr)
ES (1) ES2848215T3 (fr)
HK (1) HK1204983A1 (fr)
IL (1) IL236868B (fr)
IN (1) IN2014DN10901A (fr)
MA (1) MA37799B2 (fr)
MX (2) MX375078B (fr)
MY (1) MY183944A (fr)
NZ (2) NZ717808A (fr)
PH (1) PH12014502790A1 (fr)
SG (1) SG11201500228UA (fr)
TW (1) TWI693070B (fr)
UA (1) UA114517C2 (fr)
WO (1) WO2014015416A1 (fr)
ZA (1) ZA201409179B (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
EP1441707A1 (fr) * 2001-11-09 2004-08-04 Pharmacia AB Agent anti-muscarinique et agoniste des oestrogenes pour traiter une vessie instable ou hyperactive
US20060252734A1 (en) * 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
US8835413B2 (en) * 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20130231317A1 (en) * 2011-07-19 2013-09-05 Michael S. Riepl Dhea bioadhesive controlled release gel

Also Published As

Publication number Publication date
KR20200008055A (ko) 2020-01-22
WO2014015416A9 (fr) 2014-07-03
TWI693070B (zh) 2020-05-11
DK2877183T3 (da) 2021-03-08
CN111529536A (zh) 2020-08-14
MX375078B (es) 2025-03-06
PH12014502790B1 (en) 2015-02-09
MY183944A (en) 2021-03-17
AR091907A1 (es) 2015-03-11
MX2020009333A (es) 2020-10-08
WO2014015416A1 (fr) 2014-01-30
CN104540511A (zh) 2015-04-22
CA2879648C (fr) 2017-10-31
UA114517C2 (uk) 2017-06-26
MA37799A1 (fr) 2016-08-31
IL236868B (en) 2020-09-30
PH12014502790A1 (en) 2015-02-09
EP2877183B1 (fr) 2020-12-16
SG11201500228UA (en) 2015-02-27
KR102258122B1 (ko) 2021-05-28
ES2848215T3 (es) 2021-08-05
EP2877183A1 (fr) 2015-06-03
CL2015000169A1 (es) 2015-08-07
TW201408305A (zh) 2014-03-01
US20140045806A1 (en) 2014-02-13
AU2013296091B2 (en) 2016-01-07
ZA201409179B (en) 2015-12-23
EP2877183A4 (fr) 2016-03-09
KR20210062746A (ko) 2021-05-31
MX2015001064A (es) 2015-07-14
BR112015001479A2 (pt) 2017-07-04
JP6618887B2 (ja) 2019-12-11
EA201500165A1 (ru) 2015-07-30
HK1204983A1 (en) 2015-12-11
IL236868A0 (en) 2015-03-31
CA2879648A1 (fr) 2014-01-30
AU2013296091A1 (en) 2015-01-22
JP2017057211A (ja) 2017-03-23
JP2019196404A (ja) 2019-11-14
CA2972491C (fr) 2020-12-29
EA028263B1 (ru) 2017-10-31
JP2015522625A (ja) 2015-08-06
KR20150033696A (ko) 2015-04-01
NZ717808A (en) 2017-08-25
CA2972491A1 (fr) 2014-01-30
NZ703168A (en) 2016-04-29
KR20170095399A (ko) 2017-08-22
JP6893960B2 (ja) 2021-06-23
IN2014DN10901A (fr) 2015-09-11

Similar Documents

Publication Publication Date Title
MA38276A1 (fr) Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
MX2013007612A (es) Aumento o mantenimiento no medico del peso corporal de un mamifero.
MA40224A (fr) Anticorps se liant aux protofibrilles ass améliorés
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
TN2017000270A1 (en) Use of prg4 as an anti-inflammatory agent
MA37799B2 (fr) Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci
SI2694065T1 (en) A composition for treating a disorder of hypoactive sexual desire
PH12022550700A1 (en) Compositions and methods for glutathione enhancement for use in brain health
FR3093641B1 (fr) Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de l’altération de la fonction respiratoire
EP4588511A3 (fr) Traitements de troubles métaboliques à base de phosphatase alcaline intestinale
MA38487A1 (fr) Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age)
TH154880A (th) การปรับปรุงให้ดีขึ้นของความตื่นตัวทางเพศ, ความต้องการทางเพศ, ความเสียวสุดยอดทางเพศ และ/หรือ ความพึงพอใจ หลังการให้พราสเตอโรน (dhea) ในช่องคลอดในผู้หญิงที่ไม่มีหรือเป็นอิสระจากอาการปวดเฉียบขณะ ร่วมเพศหรืออาการอื่นๆ ของโยนีและช่องคลอดฝ่อลีบ
Mammаdbayli The Nozological Structure of Diseases of the Nervous System Which Was the Direct Cause of Death
O’Sullivan et al. The noradrenaline re-uptake inhibitor desipramine limits pro-inflammatory cytokine production in rat cortex in vivo
Asakuma Acute Low-tone Sensorineural Hearing Loss Therapy and some recent trends
Singh Clobazam/oxcarbazepine
De Almeida Peginterferon α-2a Parkinsonism in an elderly patient: case report
Ripa Antineoplastics/antiretrovirals
Chernenkov et al. The experience with the use of synbiotic in patients of a pediatric hospital
Shaver et al. Uptake Of Cell-Free Hemoglobin Impairs Cytokine Production By Macrophages
Zhao Restless legs syndrome: 2 case reports
Sokolova et al. ORGANIZATION OF SANATORIUM REHABILITATION OF WORKING-AGE DISABLED WITH DISEASES OF THE CARDIOVASCULAR SYSTEM
Ray Various toxicities: case report
Ehrstom Recurrent vulvovaginal candidiasis, vulvodynia and emotion–what is the connection?
Anuj Maheshwari et al. TO ASSESS THE EFFICACY OF FENUGREEK SEEDS EXTRACT, AS A TESTOSTERONE BOOSTER SUPPLEMENT, IN HUMAN VOLUNTEERS: AN ADD-ON STUDY